Inhibition of adenovirus-mediated gene transfer by bronchoalveolar lavage fluid

Gene Therapy

Volumn 6, Issue 4, 1999, Pages 637-642

  Bastian, A ^a   Bewig, B ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

Adenovirus; BAL; Gene transfer; Immunoglobulin

Indexed keywords

IMMUNOGLOBULIN; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY;

ADENOVIRUS; ANTIBODY TITER; ARTICLE; CELL DEATH; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE TRANSFER; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOCYTOCHEMISTRY; LUNG LAVAGE; MACROPHAGE; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS INFECTION; VIRUS INFECTIVITY; VIRUS RECOMBINANT;

ADENOVIRIDAE; ANTIBODIES, VIRAL; BRONCHOALVEOLAR LAVAGE FLUID; CELL LINE; GENE EXPRESSION; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOGLOBULINS; LUNG DISEASES;

ADENOVIRIDAE; ANIMALIA; HUMAN ADENOVIRUS TYPE 5;

EID: 0032911926     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300854     Document Type: Article

References (28)

1. Ishibashi S et al. Hypercholesterolemia in low density lipoprotein receptor kockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest 1993; 92: 883-893.
2. Zabner J et al. Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelial of patients with cystic fibrosis. Cell 1993; 75: 207-216.
3. Crystal RG et al. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nat Genet 1994; 8: 42-51.
4. Kay M. In vivo hepatic gene therapy: complete albeit transient correction of factor IX deficiency in hemophilia B dogs. Proc Natl Acad Sci USA 1994; 91: 2353-2357.
5. Yang Y et al. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA 1994; 91: 4407-4411.
6. Yang Y, Xiang Z, Ertl HCJ, Wilson JM. Upregulation of class I major histocompatibility complex antigens by interferon γ is necessary for T cell-mediated elimination of recombinant adenovirus-infected hepatocytes in vivo. Proc Natl Acad Sci USA 1995; 92: 7257-7261.
7. Kaplan JM et al. Humoral and cellular immune responses of nonhuman primates to long-term repeated lung exposure to Ad2/CFTR-2. Gene Therapy 1996; 3: 117-127.
8. Yang Y et al. Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. Nat Genet 1994; 7: 362-369.
9. Goldman MJ, Litzky LA, Engelhardt JF, Wilson JM. Transfer of the CFTR gene to the lung of nonhuman primates with E1-deleted, E2a-defective recombinant adenoviruses: a preclinical toxicology study. Hum Gene Ther 1995; 6: 839-851.
10. Worgoll S, Wolff G, Falck-Pedersen E, Crystal RG. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum Gene Ther 1997; 8: 37-44.
11. Rosenfeld MA et al. In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell 1992; 68: 143-155.
12. Zabner J et al. Safety and efficiency of repetitive adenovirus-mediated transfer of CFTR cDNA to airway epithelia of primates and cotton rats. Nat Genet 1994; 6: 75-83.
13. Kay MA et al. Long-term hepatic adenovirus-mediated gene expression in mice following CTLA41g administration. Nat Genet 1995; 11: 191-197.
14. Yang Y, Li Q, Ertl HCJ, Wilson JM. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol 1995; 69: 2004-2015.
15. Kass-Eisler A et al. The impact of developmental stage, route of administration and the immune system on adenovirus-mediated gene transfer. Gene Therapy 1993; 1: 395-402.
16. Dai Y et al. Cellular and humoral immune response to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc Natl Acad Sci USA 1995; 92: 1401-1405.
17. Zsengeller ZK et al. Persistence of replication-deficient adenovirus-mediated gene transfer in lungs of immune-deficient (nu/nu) mice. Hum Gene Ther 1995; 6: 457-467.
18. Ginsberg HS et al. Role of early region E (E3) in pathogenesis of adenovirus disease. Proc Natl Acad Sci USA 1989; 86: 3823-3827.
19. Vilquin JT et al. FK506 immunosuppression to control the immune reactions triggered by first-generation adenovirus-mediated gene transfer. Hum Gene Ther 1995; 6: 1391-1401.
20. Yang Y, Trinchieri G, Wilson JM. Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung. Nature Med 1995; 1: 890-893.
21. Van Ginkel FW et al. Intratracheal gene delivery with adenoviral vector induces elevated systemic IgG and mucosal IgA antibodies to adenovirus and β-galactosidase. Hum Gene Ther 1995; 6: 895-903.
22. Brody SL et al. Acute responses of non-human primates to airway delivery of an adenovirus vector containing the human cystic fibrosis transmembrane conductance regulator cDNA. Hum Gene Ther 1994; 5: 821-836.
23. Valentine RC, Pereira HG. Antigens and structure of the adenovirus. J Mol Biol 1965; 13: 13-20.
24. Mastrangeli A et al. 'Sero-switch' adenovirus-mediated in vivo gene transfer: circumvention of anti-adenovirus humoral immune defenses against repeat adenovirus vector administration by changing adenovirus serotype. Hum Gene Ther 1996; 7: 79-87.
25. Rennard SI, Crystal RG. Fibronectin in human bronchopulmonary lavage fluid. J Clin Invest 1981; 69: 113-122.
26. Teschler H et al. Elevated levels of bronchoalveolar lavage vitronectin in hypersensitivity pneumonitis. Am Rev Respir Dis 1993; 147: 332-337.
27. 5 promote adenovirus internalization but not virus attachment. Cell 1993; 73: 309-319.
28. Hersh J, Crystal RG, Bewig B. Modulation of gene expression after replication-deficient, recombinant adenovirus-mediated gene transfer by the product of a second adenovirus vector. Gene Therapy 1995; 2: 124-131.